ALAMEDA, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American ...
BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset ...
BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...
BioTime, Inc.Peter GarciaChief Financial Officer510-521-3390, ext 367orJudith Segall510-521-3390, ext 301 BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice ...
BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback